| Name | Title | Contact Details |
|---|
To be the Best Community Healthcare System in New England. About Rutland Regional Medical Center The biggest community hospital in Vermont and the second largest hospital in the state, Rutland Regional Medical Center has been providing high quality healthcare to the Rutland Region for more than 100 years. As the needs of our community have grown and changed, so has Rutland Regional, adding services, staff and facilities. Today, Rutland Regional Medical Center is a 144 bed hospital, employing over 1,600 professional and support staff including 227 providers trained in 36 specialty areas. Providing preventive, diagnostic, acute and rehabilitative services, Rutland Regional Medical Center serves Rutland County, portions of southern and central Vermont and communities in eastern New York State. The hospital`s medical staff is supported by excellent nurses, high quality diagnostic and ancillary services and a broad array of sophisticated equipment technology, including advanced diagnostic imaging, a top-of-the-line linear accelerator used in the treatment of cancer patients, and a diagnostic Cardiovascular and Angiographic Lab. At Rutland Regional we manage and adapt to change and growth while continuing our focus on a high standard of personalized, quality medical care, adding key specialties to serve community needs, and focusing on attracting and recruiting highly trained doctors, nurses and staff. We are committed to providing the services, both in and out of the hospital, required to maintain the health of not just our patients, but the entire community
Fallon Medicca is a Tinton Falls, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cenorin is a Kent, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TeleMed Systems is a Hudson, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.